PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Circ Res. Author manuscript; available in PMC 2014 April 12.
Published in final edited form as:
PMCID: PMC3700369
NIHMSID: NIHMS466204

Mitochondria and Endothelial Function

Abstract

In contrast to their role in other cell types with higher energy demands, mitochondria in endothelial cells primarily function in signaling cellular responses to environmental cues. This article provides an overview of key aspects of mitochondrial biology in endothelial cells, including subcellular location, biogenesis, dynamics, autophagy, ROS production and signaling, calcium homeostasis, regulated cell death, and heme biosynthesis. In each section, we introduce key concepts and then review studies showing the importance of that mechanism to endothelial control of vasomotor tone, angiogenesis, and inflammatory activation. We particularly highlight the small number of clinical and translational studies that have investigated each mechanism in human subjects. Finally, we review interventions that target different aspects of mitochondrial function and their effects on endothelial function. The ultimate goal of such research is the identification of new approaches for therapy. The reviewed studies make it clear that mitochondria are important in endothelial physiology and pathophysiology. A great deal of work will be needed, however, before mitochondria-directed therapies are available for the prevention and treatment of cardiovascular disease.

Keywords: mitochondria, endothelium, biogenesis, mitophagy, apoptosis

Introduction

A large body of work has shown that endothelial dysfunction contributes to the pathogenesis of cardiovascular disease,1 and considerable effort has been made to define operative mechanisms. Recent work has emphasized the importance of mitochondria for endothelial function. While they have long been recognized for their role in bioenergetics, mitochondria participate in a host of other cellular processes. In contrast to cardiac myocytes and other cell types, energy requirements in the endothelium are relatively low and glycolysis is the major source of ATP production.2 It is now recognized that endothelial mitochondria play a prominent role in signaling cellular responses to environmental cues.3 An important mode of mitochondrial signaling is the regulated production of reactive oxygen species (ROS).4 Cardiovascular risk factors are associated with excess mitochondrial ROS production that promotes inflammation and decreases nitric oxide bioavailability.

This article will review key aspects of mitochondrial biology in endothelial cells, including subcellular location, biogenesis, dynamics, mitophagy, ROS production, calcium homeostasis, regulated cell death, and heme synthesis. Since many of these topics are covered in great detail by other papers in this Circulation Research Review Series, we will not provide a detailed discussion of each area or extensively review findings in cardiac myocytes or other cell types. Instead, we provide an introduction to the key concepts and describe experimental work in endothelial cells. Each section concludes with a review of the available human studies relating mitochondrial and endothelial dysfunction in cardiovascular vascular disease. Our final section describes experimental and clinical studies of mitochondria-directed interventions and their effects on endothelial function.

Mitochondrial Content and Subcellular Location in Endothelial Cells

Mitochondrial content in endothelial cells is modest compared to other cell types with higher energy requirements. In the rat, for example, mitochondria occupy 2–6% of cytoplasmic volume in endothelial cells compared to 32% in cardiac myocytes.5,6 Mitochondrial content varies by vascular bed and may relate to function. For example, highly active endothelial cells at the blood-brain barrier have a higher mitochondrial content (8–11%) compared to endothelial cells in other capillary beds.6 Mitochondrial distribution within the cell has been predicted to influence mitochondrial signaling in the endothelium.7 Consistent with this idea, a recent study demonstrated that perinuclear clustering of mitochondria and diffusion of mitochondria-derived ROS into the nucleus contributes to the regulation of hypoxia-sensitive genes in rat pulmonary endothelial cells.8

A few translational studies have examined the importance of subcellular location for signaling by mitochondria in human subjects. In arterioles isolated from human myocardium, for example, mitochondria are anchored to the cytoskeleton and release ROS in response to cell deformation by shear stress.9 In this setting, ROS release signals nitric oxide production and flow-mediated dilation.

Mitochondrial Biogenesis and PGC-1α in the Endothelium

Mitochondrial content depends on the balance between mitochondrial biogenesis and mitophagy (Figure 1). The formation of new mitochondria is a complex and incompletely understood process involving replication of mitochondrial DNA (mtDNA) and expression of nuclear and mitochondrial genes. The peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) plays a primary role in this process.10,11 PGC-1α activates nuclear respiratory factor (NRF)- and −2 to coordinate expression of nuclear genes required for biogenesis. PGC-1α also activates transcription factor A, mitochondrial (TFAM) and transcription factor B, mitochondrial (TFBM), which regulate the expression of genes coded by mtDNA, including genes for subunits of the electron transport chain.

Figure 1
Conceptual illustration of the mitochondrial life cycle and the contribution of mitochondrial dynamics and mitophagy to quality control. Biogenesis is regulated by PGC-1α which activates NRF-1,2 and TFAM and TFBM. Mitochondria undergo cycles of ...

Studies in non-vascular tissues have shown that stimuli for mitochondrial biogenesis, such as hypoxia, calorie restriction, exposure to cold, and exercise, act by increasing the expression and activity of PGC-1α.10,11 Expression of PGC-1α is controlled by multiple factors, including nitric oxide, sympathetic beta receptor activation, calcineurin, cAMP, AMP-activated protein kinase (AMPK), p53, and calcium/calmodulin-dependent protein kinase. Post-translational modifications further regulate PGC-1α activity. For example, PGC-1α is phosphorylated by AMPK, p38 mitogen-activated protein kinase (MAP kinase), Akt, and glycogen synthase kinase-3 (GSK3). PGC-1α activity also depends on its acetylation state; activity is increased by sirtuin-mediated deacetylation and decreased by the acetyltransferase GCN5.12

In addition to its role in mitochondrial biogenesis, PGC-1α also coordinates expression of numerous genes related to glucose and lipid metabolism in cardiac myocytes and other cell types.11,13 In general, PGC-1α is activated in states of increased energy demand and serves to augment cellular capacity for ATP production. PGC-1α also regulates expression of vascular endothelial growth factor-1 (VEGF-1) and stimulates angiogenesis.14 Given the energy demands in cardiac myocytes, it is perhaps not surprising that PGC-1α plays an important role in regulating metabolism, and it is known that genetic deletion causes heart failure. Furthermore, cardiac PGC-1α expression is altered in diabetes mellitus and pressure overload and contributes to the pathogenesis of heart failure in these settings.13,15

Since energy demands are lower, it is interesting to consider that PGC-1α might play a different role in endothelial cells. It is known that PGC-1α is expressed in endothelial cells and regulates mitochondrial biogenesis.10 Additionally, PGC-1α orchestrates cellular defenses against oxidative stress that includes many mitochondrial proteins. In this regard, overexpression of PGC-1α by adenoviral transfection increases expression of uncoupling protein-2 (UCP2) and mitochondrial antioxidant enzymes, including manganese superoxide dismutase (MnSOD), catalase, and thioredoxin 2 (TRX2), while silencing PGC-1α has the opposite effect.16 PGC-1α overexpression protects against apoptosis, limits inflammatory activation, prevents activation of c-Jun N-terminal kinase (JNK), and improves nitric oxide bioavailability.16,17 It has further been argued that PGC-1α-induced mitochondrial biogenesis protects against oxidative stress by supplying undamaged mitochondria that produce less ROS.18

Despite the favorable effects on endothelial phenotype, it is uncertain whether augmenting PGC-1α will prove useful as an anti-atherosclerosis strategy. Unexpectedly, PGC-1α−/− mice bred onto an ApoE−/− background did not have increased lesion formation.19 Interpretation of this finding is complicated, however, because PGC-1α−/− mice are lean and hyperactive, which would tend to limit atherogenesis. In addition, increased expression of PGC-1β may compensate for the loss of PGC-1α.20 Studies with endothelium-specific or double knockout animals may be required sort out these possibilities.11 A very recent pilot study showed that endothelial-specific overexpression of PGC-1α protects against angiotensin II-induced hypertension.21

In regard to clinical studies, it is well established that PGC-1α gene expression and mitochondrial mass are lower in skeletal muscle of patients with diabetes mellitus, resulting in insulin resistance and impaired bioenergetics.2224 In regard to the endothelial cells, mitochondrial content is lower in tissue collected from patients with pulmonary hypertension.25 A recent study showed lower mitochondrial mass in arterioles isolated from patients with diabetes mellitus by biopsy of subcutaneous fat.26 Epidemiological studies have shown that PGC-1α polymorphisms are associated with hypertension,27 carotid atherosclerosis,28 and coronary artery disease,29 suggesting links with vascular disease. It is important to recognize that such observational studies do not prove decreased mitochondrial mass or function in the endothelium is important, given that PGC-1α regulates so many other aspects of metabolism. Overall, however, the available studies suggest that interventions that activate PGC-1α and stimulate mitochondrial biogenesis protect against cardiovascular disease, and efforts are underway to identify small molecules that may be developed as drugs.30

Mitochondrial Dynamics in Endothelial Cells

Although traditionally viewed as discrete organelles, it is now recognized that mitochondria form networks and undergo cycles of fusion and fission in many cell types, including cardiac myocytes31 and endothelial cells (Figure 1).18 This process of mitochondrial dynamics has been extensively reviewed.18,32 Briefly, fusion of the outer mitochondrial membrane is mediated by the transmembrane GTPases mitofusin-1 and mitofusin-2 (MFN1, MFN2), while fusion of the inner membrane is controlled by optic atrophy protein 1 (OPA1). Fission is mediated by dynamin-related protein-1 (DRP1) and Fission-1 (FIS1). FIS1 recruits DRP1 to mitochondria to initiate fission.33 DRP1 translocation is inhibited by phosphorylation at serine-656 by AMPK and activated by the phosphatase calcineurin.34

Under physiological conditions, fusion and fission are balanced and mitochondrial networks are present. Fusion facilitates distribution of metabolites, proteins, and mtDNA and helps maintain electrical and biochemical connectivity. Likewise, fission is important for normal cell function. For example, fission is required for cell division and movement of mitochondria within the cell and is involved in the elimination of senescent mitochondria.18 Fission is also an adaptive response to cellular stress that facilitates the isolation and removal of damaged mitochondria components by mitophagy as discussed in the next section.18 Finally, mitochondrial fission occurs concomitantly with outer membrane permeabilization and release of cytochrome c during apoptosis, although it remains controversial whether fission is a necessary step in mitochondria-dependent apoptosis.32,35

Recent studies suggest that mitochondrial dynamics are relevant to endothelial cell function. For example, silencing MFN1 and inhibiting fusion reduces angiogenic responses to vascular endothelial growth factor (VEGF) and Akt-dependent activation of endothelial nitric oxide synthase (eNOS).36 Networks are present in endothelial cells under physiological conditions, but fragmentation is observed following exposure to hydrogen peroxide,37 high glucose,38,39 and ischemia-reperfusion injury.40 Endothelial expression of DRP1 and FIS1 is increased and expression of OPA1 is decreased in experimental diabetes.39 Silencing FIS1 or DRP1 under conditions of high glucose maintains eNOS activity and NO bioavailability likely by decreasing mitochondrial ROS.39

There is emerging evidence that mitochondrial dynamics are altered in the endothelium of patients with cardiovascular risk factors. For example, a recent study showed mitochondrial fragmentation and increased FIS1 in freshly isolated endothelial cells from patients with diabetes mellitus.39 Polymorphisms in the OPA1 and MFN2 genes are associated with hypertension.41,42 These studies suggest links between mitochondrial dynamics and vascular disease and raise the possibility that interventions directed toward restoring normal dynamics might have therapeutic benefit.

Autophagy and Mitophagy in Endothelial Cells

Autophagy is a cellular mechanism for controlled degradation of proteins, macromolecules, and organelles.4346 Autophagy provides energy when the cell is deprived of nutrients and eliminates damaged organelles under conditions of cellular stress. The process involves formation of the double-membrane autophagosome that engulfs and isolates cellular components targeted for degradation. The autophagosome subsequently merges with a lysosome, where the contents and inner membrane are degraded by acid hydrolases and recycled for use by the cell. Mechanisms of autophagy have been extensively reviewed,4345 including a review by Kubli and Gustafsson for this Series on Mitochondria in Health and Disease.46

Mitophagy refers to the selective autophagy of mitochondria (Figure 1). As mitochondrial damage accumulates, networks undergo rearrangement and fission to yield different populations of daughter mitochondria. Those with normal membrane potential and preserved components can be reincorporated into networks, while dysfunctional progeny are targeted for elimination.18,44 It has been suggested that this process purges the cell of vulnerable mitochondria that otherwise would undergo outer membrane permeabilization and induce apoptosis.44 It is interesting that stimuli for mitophagy also activate PGC-1α and biogenesis, thus providing fresh replacements for eliminated mitochondria.47 Thus, dynamics, mitophagy, and biogenesis provide a unified mechanism for mitochondrial quality control.

Membrane depolarization is an important trigger for mitophagy.44 Under physiological conditions, phosphatase and tensin homolog-induced putative kinase protein-1 (PINK1) is imported into mitochondria and degraded via a process that depends on mitochondrial membrane potential. Membrane depolarization leads to accumulation of PINK at the mitochondrial surface and recruitment of the E3 ubiquitin ligase Parkin, and may de-repress Beclin-1 to activate mitophagy. Ubiquitylation of mitochondrial surface proteins leads to binding and degradation of p62 and targets the mitochondria for enclosure in an autophagosome and eventual degradation. Autophagosome formation and maturation involves a number of proteins, including microtubule-associated protein 1 light chain 3 (LC3)-I, which is an ubiquitin-like protein that conjugates phosphatidylethanolamine to form LC3-II. Mitochondria can also be targeted for autophagy through the action of NIX, which associates with the mitochondrial membrane and interacts with LC3.44

A growing body of work suggests that impaired autophagy and mitophagy contribute to the pathogenesis of disease.45 PINK and Parkin-mediated mitophagy has received considerable attention because impairment of this mechanism in dopaminergic neurons plays a role in hereditary forms of Parkinson’s disease.43 Dysregulation of autophagy in a variety of tissues has also been linked to diabetes mellitus, atherosclerosis, and reduced lifespan.18,48 Impaired autophagy in cardiac myocytes contributes to the pathogenesis of hypertensive heart disease.49 Depending on the specific setting and degree of impairment, loss of autophagy may be protective or have pathological effects in regard to atherosclerotic cardiovascular disease.50,51 Overall, however, autophagy appears to be an adaptive response in the endothelium, and interventions that promote autophagy tend to improve vascular function.48

Several recent studies have specifically examined mitophagy in endothelial cells under conditions of oxidative stress and energy deprivation. Exposure of cultured endothelial cells to hydrogen peroxide or the glycolysis blocker 2-deoxyglucose activates AMPK and stimulates autophagosome formation as reflected by conversion of LC3-I to LC3-II.52 Oxidative damage induced by mitochondria-targeted irradiation of endothelial cells promotes Parkin translocation to depolarized mitochondria and increases LC3-II formation.47 Exposure of endothelial cells to hemin promotes lipid peroxidation, leads to mitochondrial depolarization, and stimulates mitophagy.53 Interestingly, Beclin-1/LC3-II-mediated autophagy is also a mechanism for clearance of oxidized low-density lipoprotein (ox-LDL) in endothelial cells.54 Thus, autophagy and mitophagy appear to be important responses to oxidative stress in the endothelium.

Altered mitochondrial quality control has been related to endothelial dysfunction in aging. For example, disordered mitochondrial dynamics and loss of membrane potential are observed in cell culture models of senescence.55 Overexpression of autophagy proteins ATG5, ATG12, and LC3B extends the lifespan of cultured endothelial cells, and these effects are associated with improved mitochondrial fitness, as evidenced by higher membrane potential and ATP production and decreased damage to mtDNA.47 A recent study demonstrated higher p62 (suggesting an impairment of p62 degradation that normally occurs during autophagosome formation), lower Beclin-1 expression, and impaired autophagic flux, as well as higher superoxide production and blunted endothelium-dependent dilation in aortic tissue of aged mice. These abnormalities were reversed by treatment of the animals with trehalose, a dietary supplement that stimulates autophagy.56

Relatively few human studies have examined autophagy in relation to cardiovascular disease. Expression of autophagy markers, including Beclin-1, ATG5, and LC3-II, is altered in myocardial tissue from patients with dilated cardiomyopathy, and these markers are restored by mechanical unloading.57 Supporting previous work in mice,58 a recent study showed that exercise activates autophagy in skeletal muscle obtained by biopsy from older overweight women.59 Although it is well known that exercise improves endothelial function,1 it remains uncertain whether enhanced autophagy contributes to this effect. A recent translational study showed that p62 protein expression was higher and Beclin-1 expression was lower in endothelial cells biopsied from older healthy human subjects, consistent with impaired autophagy.56 Furthermore, lower Beclin-1 expression correlated with impaired endothelium-dependent dilation in the forearm. Overall, the available experimental and human data suggests that enhancing autophagy in the endothelium would be protective against vascular disease.

Mitochondrial ROS in Endothelial Cells

Sources of Mitochondrial ROS

Given their importance for cell signaling and vascular disease, there is considerable interest in the sources and regulation of mitochondrial ROS in endothelial cells (Figure 2). While the primary site of oxygen consumption in mitochondria is cytochrome c oxidase (Complex IV), it has been estimated that superoxide anion formation at Complexes I and III accounts for 0.1 to 2% of the total.4,60,61 These estimates are based on studies of isolated mitochondria, however, and the percentage attributable to ROS production in endothelial cells in vivo remains uncertain.61

Figure 2
Illustration of mitochondrial membrane components in endothelial cells related to ROS generation. I, II, III, IV, V = Complexes I–V of the electron transport chain; ABC-me = ATP-binding cassette-mitochondrial erythroid; ALA = amino levulinic acid; ...

In addition to Complexes I and III, several other sources of mitochondrial ROS have been identified. For example, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4 (NOX4) is highly expressed in endothelial cells and has been localized to mitochondria in other tissues, although mitochondrial localization in endothelial cells remains uncertain.62 As has been recently reviewed, NOX4 serves as an important convergence point for ROS signaling and contributes to endothelial cell senescence, migration, angiogenesis, and adaptive responses to hypoxia, inflammation and oxidative stress.63

The monoamine oxidase (MAO) family of enzymes is localized to the outer mitochondrial membrane and generates ROS during catabolism of catecholamines. ROS produced by MAO-A has been implicated in maladaptive hypertrophy and apoptosis of cardiac myocytes exposed to norepinephrine.64 MAO-derived ROS are also associated with adverse cardiac remodeling and heart failure in response to pressure overload in mice.64 Hydrogen peroxide produced by MAO-A in vascular smooth muscle cells contributes to serotonin-induced vasoconstriction.65 Although endothelial cells are known to express MAO,66 its importance for endothelial function is poorly understood.

The growth factor adapter protein p66Shc is another source of ROS that functions in mitochondrial signaling. p66Shc generates hydrogen peroxide by oxidizing cytochrome c.6770 Under physiological conditions, p66Shc may be contained within a high-molecular weight inhibitory protein complex within mitochondria or the cytoplasm. Specific proapoptotic signals induce release and migration of p66Shc into the mitochondrial intermembrane space. p66Shc is also activated when the concentration of reduced cytochrome c is relatively high, such as when Complex IV activity is reduced by hypoxia or due to physiological inhibition by nitric oxide, as discussed below. Furthermore, p66Shc is activated via phosphorylation by protein kinase CβII in the setting of high glucose and contributes to the development of diabetic endothelial dysfunction.68,69 Thus, p66Shc transduces environmental signals into ROS that signal apoptosis and other cellular responses.

Another regulator of mitochondrial ROS is the mitochondrial ATP-sensitive potassium channel (mitoKATP). A consensus structure for this inner membrane channel is lacking, but remains the focus of intense study.71 Studies in cardiac myocytes have shown that mitoKATP is activated by superoxide and hydrogen peroxide and regulated in a redox-dependent manner by reactive nitrogen species.72 This channel is perhaps best known for its role in facilitating ROS-mediated ischemic preconditioning in cardiac myocytes, possibly by acting as an uncoupling agent that decreases membrane potential and mitochondrial calcium overload, although the precise mechanism remains unclear.73 In endothelial cells, mitoKATP is less well studied, but pharmacological mitoKATP activation protects against ischemic cell death in cultured endothelial cells and preserves endothelial vasodilator function in Langendorff-perfused guinea-pig hearts subjected to ischemia-reperfusion.74,75 Inhibition of mitoKATP channels also blunts high glucose-induced endothelial cell apoptosis.76

In healthy human volunteers and patients with atherosclerosis, twenty minutes of ischemia followed by reperfusion produces a marked impairment in endothelium-dependent dilation in the forearm. This impairment can be prevented by short cycles of cuff occlusion and release prior to the ischemic insult. The benefit of such ischemic preconditioning is blocked by the non-selective KATP channel blocker glibenclamide and is mimicked by the mitoKATP opener diazoxide.77,78 These human studies are limited by the non-selective and off-target effects of these pharmacological interventions, but strongly suggest that mitoKATP activation may contribute to ischemic preconditioning in the human endothelium.

It is interesting that mitochondrial ROS production can be triggered by ROS from other enzymatic sites by a process termed ROS-induced ROS release.4,79 For example, ROS produced by NADPH oxidase can stimulate mitochondrial ROS production by a mechanism that involves opening of the mitoKATP channel, membrane depolarization, and the mitochondrial permeability transition (MPT) pore.80,81. In this situation, inhibiting mitoKATP may be protective and preserves nitric oxide production in endothelial cells exposed to angiotensin II.81 Thus, ROS produced by NADPH oxidase, uncoupled nitric oxide synthase, neighboring mitochondria, and other sources can stimulate mitochondrial ROS production in a multi-directional fashion. ROS-induced ROS release may amplify and target ROS signals under physiological conditions, but when excessive, may contribute to the pathogenesis of endothelial dysfunction.81,82

Mitochondrial ROS Signaling

Mitochondria-derived hydrogen peroxide, which is generated via dismutation of superoxide by MnSOD or produced directly by NOX4 or p66Shc, can diffuse across membranes and function in physiological signaling, as has been extensively reviewed.3,4,8,52 For example, experimental studies have shown that shear stress-induced vasodilation, hypoxia signaling, autophagy, and pro-inflammatory activation, depend on mitochondrial ROS. In humans, however, there are very limited data about mitochondrial ROS in physiological cell signaling in the vasculature. The lack of benefit and, at times, harmful effects of high-dose non-selective antioxidants as treatment for cardiovascular disease in clinical trials might be interpreted as indirect evidence that ROS play a physiological role in the vasculature.83

A few clinical studies have more directly implicated ROS signaling in endothelial function. Flow-mediated dilation in arterioles isolated from human myocardium depends on the production of ROS by the electron transport chain.9 In healthy human volunteers, flow-mediated dilation of the brachial artery is blunted by oral antioxidant treatment, which might reflect scavenging of mitochondrial ROS.84 A study of arterioles isolated from adipose tissue of patients with coronary artery disease demonstrated that mitochondrial ROS compensate for the loss of nitric oxide and promote flow-mediated dilation.85 Interpretation of those results are complicated, however, because hydrogen peroxide scavengers such as N-acetylcysteine improve endothelium-dependent dilation in coronary arteries of patients with atherosclerosis.86 Indeed, it is possible that systemic antioxidant treatment could reduce pathological ROS levels in one compartment, while limiting a physiological effect in another. The relative importance of mitochondrial ROS for endothelial cell signaling is likely to vary according to vascular bed and depend on risk factor burden.

Excess Mitochondrial ROS Production

Altered mitochondrial membrane potential is an important factor that drives excess mitochondrial ROS production in the setting of risk factors. Membrane depolarization may activate ROS production by increasing the activity of Complexes I and III, as they act to restore membrane potential. Membrane hyperpolarization also leads to higher ROS production, and may be particularly relevant to metabolic disease states where there is nutrient excess and low demand for ATP. These conditions are associated with an increase in the NADH/NAD+ ratio and a decrease in the rate of electron flow that prolongs the lifespan of reactive intermediates at Complexes I and III. These intermediates promote the reduction of oxygen to superoxide anion.4,61 It has been suggested that high glucose and fatty acid levels in obesity and diabetes mellitus drive mitochondrial ROS production by this mechanism.87

It is known that nutrient excess alters mitochondrial metabolism in cardiac myocytes and contributes heart failure.88,89 In endothelial cells, where energy requirements are lower, excess substrate stimulates mitochondrial ROS production to signal a change in endothelial phenotype. For example, exposure of endothelial cells to high glucose or fatty acid concentrations decreases nitric oxide bioavailability and activates nuclear factor-κB (NF-κB) and protein kinase C.87,90 These responses are prevented by mitochondrial membrane depolarization, inhibitors of the electron transport chain, and overexpression of uncoupling protein 1 (UCP1), which may lower membrane potential as discussed below.90 Interestingly, p66Shc-derived ROS have been implicated in glucose-induced endothelial dysfunction in endothelial cells. p66Shc null mice made diabetic by streptozotocin injection are protected against the development of endothelial dysfunction and display increased expression of eNOS and heme oxygenase-1.69 Overexpression of p66Shc in diabetes is epigenetically regulated by promoter hypomethylation and histone acetylation leading to endothelial dysfunction that may persist despite restoration of normal glucose levels.68

ROS-induced modifications to mitochondrial components, including mtDNA, proteins, and lipids may further exacerbate ROS production and set up a vicious cycle that contributes to vascular disease.88,91 mtDNA damage may lead to decreased expression of electron transport chain components or expression of defective components that produce more ROS.92 Risk factors, including older age, smoke exposure, hypercholesterolemia, and hyperglycemia are associated with increased mtDNA damage in cardiovascular tissues.93 mtDNA damage correlates with the extent of atherosclerosis in mouse models and human tissues.94 It has recently been proposed that glycation of mitochondrial proteins might also alter their function and increase ROS in diabetes mellitus.95

Modified mitochondrial proteins accumulate in disease states. In the early stages of disease, the combination of dynamics, mitophagy, and biogenesis may replace damaged mitochondrial components and maintain normal mitochondrial function. However, impairment of these quality control mechanisms leads to the retention of dysfunctional mitochondria that produce excess ROS and promote vascular disease. It is interesting to note that methods are available to measure mtDNA damage in human tissues.91 Indeed, measuring oxidative damage to mtDNA in circulating leukocytes has considerable potential as a reliable marker of mitochondrial dysfunction that can be made in readily-available blood cells. However, large-scale application of this approach has not been reported.

Only a few human studies have specifically implicated mitochondria as the source of excess ROS in patients. In diabetic patients, circulating leukocytes and arterioles isolated from subcutaneous fat display higher mitochondrial ROS production and membrane hyperpolarization.26,96 Furthermore, impaired endothelium-dependent vasodilation in freshly isolated arterioles from diabetics is reversed by mild membrane depolarization or mitochondria-targeted antioxidants.26 Interestingly, a recent study showed that low glucose concentrations also stimulate mitochondrial ROS production, membrane hyperpolarization, and endothelial dysfunction in cultured cells and isolated human arterioles.97 These findings might explain clinical trials suggesting that tight glucose control might actually be harmful in diabetic patients, and suggest that mitochondria-derived ROS from any cause can induce endothelial dysfunction.97

Genetic studies suggest a link between mitochondrial proteins and hypertension. Polymorphisms in mitochondrial genes, including a subunit of Complex IV, correlate with blood pressure in the Framingham Heart Study.98 In addition, there is a maternal link in the heritability of blood pressure that may implicate the mitochondrial genome.99 However, the consequences of these polymorphisms for ROS production and their specific importance for endothelial function remain unknown.

Mitochondrial Antioxidant Enzymes

The first line of defense against mitochondrial superoxide is MnSOD. MnSOD is located in the mitochondrial matrix and catalyzes the conversion of superoxide anion to hydrogen peroxide. Consistent with a protective role in the endothelium, MnSOD+/− mice exhibit impaired endothelium-dependent vasodilation.100 In addition, ApoE−/− MnSOD+/− mice display earlier mtDNA damage and accelerated atherosclerosis compared to apoE−/− MnSOD+/+ mice.94

Levels of hydrogen peroxide are regulated by antioxidant enzymes, including catalase and several mitochondrial and cytosolic peroxidases. Catalase is located in cytosolic peroxisomes. Important mitochondrial peroxidases include TRX2, peroxiridoxin-3, and glutaredoxin-2. Glutathione peroxidase-1 is located both in mitochondria and the cytosol in endothelial cells.4,101 As noted above, increased expression of these enzymes is signaled by AMPK and PGC-1α in response to hydrogen peroxide and other forms of oxidative stress in endothelial cells.16,17 Studies in experimental models have shown that reduced expression of mitochondrial antioxidant enzymes can induce mitochondrial damage, endothelial dysfunction, and atherogenesis.94,100,102 Conversely, overexpression of these proteins is protective against the development of vascular disease.103

Uncoupling Proteins

There is considerable interest in mitochondrial uncoupling proteins and their role in the regulation of ROS production.104,105 Uncoupling proteins are located to the inner mitochondrial membrane and facilitate movement of protons down their concentration gradient into the matrix, thus making membrane potential less negative and uncoupling electron transport chain activity from ATP production. UCP1 is expressed in brown fat and plays a role in adaptive thermogenesis. UCP2, which is the primary isoform in endothelial cells, and UCP3 have high sequence homology with UCP1, but are expressed at lower levels. UCP2 and UCP3 contribute to the regulation of mitochondrial membrane potential when they are activated by superoxide and act in a compensatory fashion to decrease ROS production (Figure 2). There is controversy about how ROS dynamically activate UCP2 and UCP3. In this regard, studies have implicated protein modification by 4-hydroxynonenal and reversible glutathionylation.105107 Although uncoupling proteins may function in an adaptive manner in most circumstances, it also has been suggested that activation of uncoupling proteins in myocytes under conditions of nutrient excess may increase ROS production in the electron transport chain. This effect may lead to increased myocardial oxygen consumption, and reduced cardiac efficiency in type 2 diabetes mellitus.108

Experimental studies confirm the importance of UCP2 in endothelial cells. Decreasing expression with antisense oligonucleotides increases mitochondrial membrane potential and ROS production.104 Conversely, UCP2 overexpression reduces ROS production and inflammatory activation in cultured cells and improves endothelium-dependent dilation in isolated rat aorta.109 Expression of UCP2 is dynamically regulated, and exposure to ROS, nutrient excess, and other forms of cellular stress stimulate UCP2 expression as part of a stress response coordinated by AMPK and PGC-1α, as discussed above.16,17 In vivo studies have shown increased atherosclerosis, ischemic stroke, and impaired endothelium-dependent vasodilation in UCP2 null mice.110112

There is epidemiological evidence that UCP2 may relate to human cardiovascular disease. For example, the 866 G>A variant is associated with increased UCP2 expression and a decrease in the incidence of cardiovascular disease events.113 Polymorphisms at this loci may also be associated with carotid artery atherosclerosis.114 Interpretation of these findings is complicated by the observation that UCP2 and UCP3 gene variants are also linked to incident type 2 diabetes mellitus.115 The direct importance of uncoupling protein for the regulation of endothelium-dependent vasodilation or other aspects of endothelial function has not been directly examined in humans.

Nitric Oxide

Nitric oxide is another important regulator of mitochondrial bioenergetics and oxidant production. The effects of nitric oxide are complex and depend on the relative availability of oxygen and nitric oxide as well as the cellular redox state.116 Nitric oxide inhibits Complex IV (cytochrome c oxidase) by competing with oxygen binding at the binuclear heme a3/CuB center. In endothelial cells with physiological levels of bioactive nitric oxide, this interaction inhibits mitochondrial respiration and facilitates ROS signaling.4,116 When cellular levels of reduced glutathione are relatively low in states of oxidative stress, nitric oxide has a chronic inhibitory effect on Complex I via S-nitrosylation in a manner that blunts mitochondrial ROS production. High levels of nitric oxide, which may occur in acute inflammatory states, blunt mitochondrial reserve capacity in endothelial cells, which may reflect a decreased ability to respond to cellular stress.117 Conditions that reduce endothelial nitric oxide bioavailability may promote excess mitochondrial ROS production by withdrawing the inhibitory effects of nitric oxide.4,97 Under such conditions, peroxynitrite formed by the reaction of nitric oxide and superoxide may modify Complexes I and III in a manner that further increases ROS production.81 Antioxidant enzymes, including MnSOD are also inactivated by peroxynitrite, further exacerbating oxidative stress within mitochondria.118

Mitochondria and Calcium Homeostasis in the Endothelium

Cytosolic calcium levels regulate many aspects of endothelial function. For example, receptor-dependent agonists such as acetylcholine and serotonin activate eNOS by increasing cytosolic calcium and stimulating the binding of calcium/calmodulin.119 Calcium activates calcium/calmodulin-dependent protein kinase II (CamKII), which plays a role in eNOS gene expression and phosphorylation state and regulates actin cytoskeletal elements that influence endothelial cell shape, motility, and barrier function.120 Calcium is also involved in VEGF signaling and angiogenic functions of the endothelium.121

As has been extensively reviewed,122125 mitochondria and the endoplasmic reticulum (ER) cooperate in the regulation of calcium trafficking and thereby control key aspects of endothelial function. In brief, mitochondria serve as calcium buffer site and regulate calcium uptake and release by the ER.123,124 Although, the ER is the major storage site, approximately 25% of cellular calcium is localized to mitochondria. During cell stimulation, continuous flux of calcium through mitochondria is needed for store-operated entry and ER calcium store refilling.126 Localized calcium uptake as well as the position of mitochondria in relation to the plasma membrane produce calcium microdomains that are important in these processes.124,125,127

Calcium movement in and out of mitochondria is highly regulated.124,125 Generally speaking, the availability of multiple uptake and extrusion channels serves to buffer mitochondrial calcium levels over the physiological range of cytosolic calcium. When calcium load exceeds the buffering threshold, mitochondrial calcium increases rapidly and may trigger mitochondrial-dependent apoptosis. In endothelial cells, hydrogen peroxide-induced increases in mitochondrial calcium may depend, in part, on decreased calcium extrusion via inhibition of the sodium/calcium exchanger.128 Since calcium flux through mitochondria are important for ER calcium stores, inhibition of calcium extrusion by hydrogen peroxide may deplete ER calcium stores and thereby trigger the unfolded protein response and apoptosis.125,126

The ER maintains specific domains for direct interaction with mitochondria known as the mitochondria-associated membrane (MAM). As has recently been reviewed, the MAM tethers the ER to mitochondria and is enriched with proteins relevant to calcium and lipid metabolism. MAM’s facilitate calcium exchange that are important for ER regulation of mitochondrial energetics and apoptosis.129

A recent study suggests that MAM’s are relevant to pulmonary hypertension. In pulmonary arterial vascular smooth muscle cells, disruption of mitochondria-ER interactions by the reticulon protein Nogo-B impairs hypoxia-induced apoptosis, leading to the typical proliferative lesions seen in pulmonary hypertension.130 Interestingly, Nogo-B expression is also increased in endothelial cells in pulmonary hypertension, and it has been suggested that endothelial cells may also assume a proliferative apoptosis-resistant phenotype in this condition. However, the specific importance of Nogo-B and other aspects of MAM biology have not been extensively studied in endothelial cells.

Physiological changes in mitochondrial and cytosolic calcium concentrations have important regulatory effects on many aspects of mitochondrial function, including ROS production, energetics, motility, dynamics, and biogenesis.4,123 Calcium activates Krebs cycle enzymes and oxidative phosphorylation, thus increasing ATP production.124,129 Cytosolic calcium regulates mitochondrial motility through the Miro-Milton protein complex, which interacts with the outer mitochondrial membrane and couples mitochondria to microtubules.125,131 Miro acts as a calcium sensor and is responsible for the retention of mitochondria in regions of high calcium levels. Cytosolic calcium plays a role in mitochondrial dynamics through calcineurin, which activates DRP1 and stimulates mitochondrial fission.18,124,131 Finally, mitochondrial calcium is an important regulator of mitochondrial biogenesis and increases expression of PGC-1α.124

There is evidence that altered mitochondrial calcium contributes to endothelial responses in pathological states. For example, high glucose increases cytosolic and mitochondrial calcium and alters histamine signaling in cultured human endothelial cells.38 Mitochondrial calcium uptake and ROS production are required for the shedding of cell membrane receptors for tumor necrosis factor-alpha (TNF-α) in response to TNF-α stimulation. This compensatory effect blunts the extent of endothelial activation under pro-inflammatory conditions.132

A recent human study examined the transient receptor potential vanilloid type 4 (TRPV4) channel, a cell membrane mechanosensitive calcium channel, in myocardial arterioles isolated from patients with coronary artery disease.133 In that study, activation of TRPV4 channels stimulated calcium entry, mitochondrial ROS release, and endothelium-dependent vasodilation.133 It has been suggested that TRPV4 channels are localized in close proximity to mitochondria associated with cytoskeletal elements,9,133 and may provide an example of how calcium microdomains contribute to mitochondrial ROS signaling in humans. Overall there is a paucity of translational studies of mitochondrial calcium flux in the endothelium.

Mitochondrial Regulation of Endothelial Cell Death

Mitochondria are implicated in cell death pathways, including apoptosis and programmed necrosis (necroptosis).46,134 Necroptosis is initiated by death receptors, such as TNF receptor 1, and involves the activities of receptor-interacting protein 1 (RIP1) and 3 (RIP3).135,136 Studies suggest that mitochondria contribute to necroptosis execution. For example, TNF-α-induced necrosis requires the formation of protein complexes that include RIP1 and RIP3 and the mitochondrial phosphoglycerate mutase/protein phosphatase (PGAM5) at the mitochondrial outer membrane.137 Interestingly, PGAM5 activates DRP1 by dephosphorylation, thus facilitating mitochondrial fragmentation.137 Nitration of mitochondrial complex I and membrane depolarization also contribute to necroptosis in endothelial cells.138 Although myocardial cell necroptosis contributes to ischemic injury and heart failure,135 relatively little is known about the importance of this process in the endothelium.

Mitochondria are also central mediators of apoptosis.32,139,140 Briefly, intrinsic apoptosis is initiated by cellular stressors, including hypoxia, ROS, oxLDL, and DNA damage. Such stimuli activate BH3-only proteins, which inhibit anti-apoptotic factors, including BCL-2, and allow activation of BAX and BAK. It is generally held true that these pro-apoptotic factors induce mitochondrial outer membrane permeabilization, depolarization, and opening of the MPT pore and the release of mitochondrial proteins into the cytosol.32,123,139 However, recent studies have questioned the role of MPT pore opening in intrinsic apoptosis.141 The intrinsic apoptosis pathway also involves mitochondrial fission, as DRP1 and BAX/BAK cooperate in the induction of outer membrane permeabilization and fission.32,140,142 Release of cytochrome c, second mitochondria-derived activator of caspases (Smac)/DIABLO, HtrA2/Omi, and other mitochondrial proteins activate caspases and apoptosis.139

The MPT pore has received considerable attention because of its possible role in cell death pathways as well as its role in ischemia-reperfusion injury and ischemic preconditioning. As recently reviewed, the MPT pore is believed to be a multi-component and relatively large, non-selective channel. 143 While the essential and non-essential components of the MPT pore remain highly controversial, both adenine nucleotide translocase (ANT) and cyclophilin D serve regulatory functions, and the roles of the voltage-dependent anion channel (VDAC) and BAX have been established as nonessential.143145 Under physiological conditions, the pore is functionally closed. In vitro experiments with endothelial cells suggest that short MPT openings may serve a protective function, dissipating membrane potential in response to oxidative stress or calcium overload, while lengthy MPT openings may trigger apoptosis.80,123,141 However, it remains uncertain whether short or prolonged MPT opens contribute to physiological or pathological processes in vivo.

In the endothelium, cardiovascular risk factors can trigger apoptosis by multiple mechanisms. Apoptosis is observed in cells exposed to high glucose and in animal models of diabetes, and under these conditions apoptosis is inhibited by interventions that decrease ROS or inhibit MPT pore opening.146,147 Hyperglycemia-induced apoptosis has been shown to involve activation of NF-κB and protein kinase C, which as discussed above, can activate p66Shc and trigger the MPT pore.67,68 Down-regulation of connexin 43 in the inner mitochondrial membrane in retinal endothelial cells also contributes to apoptosis under high glucose conditions.148 In cardiac myocytes, connexin 43 is known to play a role in ischemic preconditioning,149 possibly by functioning as an uncoupling protein or potassium channel to decrease mitochondrial ROS.150 Another reported stimulus for apoptosis in endothelial cells and renal podocytes is phosphorylation of DRP1 at serine-600 by Rho-associated coiled coil-containing protein kinase 1 (ROCK1).34,151 This mechanism may have clinical relevance because ROCK1 inhibitors are in development as drugs.151 As discussed above, DRP1 is also activated by dephosphorylation at serine-656 by calcineurin in response to increased cytosolic calcium, suggesting multiple regulatory mechanisms that link mitochondrial dynamics and calcium signaling with apoptosis.

In addition to diabetes, other risk factors may provoke apoptosis in endothelial cells. Senescent endothelial cells are more sensitive to pro-apoptotic stimuli,152 which may attributable in part to decreased expression of BCL-2.153 Relevant to hypertension, angiotensin II induces apoptosis in cultured endothelial cells.154 As discussed above, angiotensin II-stimulated apoptosis represents an example of ROS-induced ROS signaling, and is mediated by NADPH oxidase, protein kinase C, mitochondrial ATP-sensitive potassium channels, and peroxynitrite formation.81 The effects of angiotensin II are blunted by overexpression of the mitochondrial peroxidase TRX2, further suggesting that mitochondrial ROS play a role in this response.103 Relevant to dyslipidemia and atherosclerosis, oxLDL has been shown to induce apoptosis in endothelial cells by increasing mitochondrial ROS and activating p53, which leads to BAX translocation to the mitochondrial membrane and release of cytochrome c.155,156

Several human studies suggest that endothelial apoptosis may be important in vascular disease. For example, serum from patients with heart failure induces apoptosis in cultured endothelial cells, as reflected by DNA fragmentation and mitochondrial cytochrome c release.157 In addition, circulating endothelial microparticles from heart failure patients display increased markers of apoptosis. Similarly, serum from patients with acute coronary syndrome induces endothelial cell apoptosis, and the effect was blunted by treatment with an angiotensin-converting enzyme inhibitor.158 Although the circulating factors that induced endothelial cell apoptosis were not identified in those studies, similar changes were induced in isolated endothelial cells by TNF-α, which is known to be increased in patients with heart failure and coronary artery disease.157 Finally, study of surgical specimens from patients undergoing carotid endarterectomy demonstrated endothelial apoptosis in regions of low shear stress, which are known to be prone to atherosclerosis.159 Overall, these limited human studies show associations between mitochondria-regulated cell death pathways and cardiovascular disease and may suggest targets for therapy.

Heme Synthesis and Metabolism in the Endothelium

The mitochondrion is the site of heme synthesis.160 Heme is essential for the function of electron transport chain complexes and a variety of other proteins including eNOS. Heme synthesis begins with the formation of amino levulinic acid (ALA) by ALA synthase-1. ALA is then transported from the mitochondrion to the cytoplasm where it is converted to co-proporphyrinogen III. This intermediate is transported back into the mitochondrion and converted to protoporphyrin IX. Ferrous iron (Fe2+) is incorporated into protoporphyrin IX to form heme.

In addition to providing enzyme prosthetic groups, heme synthesis may function to reduce oxidative stress by sequestering redox active iron that would otherwise promote ROS formation. Inhibition of heme synthesis in rats is associated with decreased nitric oxide production and impaired endothelium-dependent vasodilation.161 Interestingly, expression of ALA synthase-1 is regulated by PGC-1α,162 possibly coordinating heme synthesis with other cytoprotective responses such as mitochondrial biogenesis and expression of antioxidant enzymes.

The mitochondrial inner membrane transport protein ATP-binding cassette-mitochondrial erythroid (ABC-me) plays a role in heme synthesis and reduction of oxidative stress. ABC-me expression is regulated by heme and was initially recognized because of its role in erythropoiesis.163,164 ABC-me is believed to function as an ALA transporter and to stabilize mitoferrin 1, a mitochondrial iron importer. Interestingly, cardiac ischemia-reperfusion injury in mice heterozygous for ABC-me (ABC-me+/−) is associated with increased ROS production, oxidative damage to mitochondria and the sarcoplasmic/endoplasmic reticulum calcium/ATPase pump (SERCA), impaired mitochondrial respiration, and more severe cardiac dysfunction.164 These effects may be attributable to altered heme synthesis and mitochondrial iron homeostasis. A preliminary study demonstrated that ABC-me is expressed in endothelial cells and that high glucose lowers ABC-me expression, which might inhibit heme synthesis and thereby contribute to mitochondrial ROS production and vascular dysfunction.165

Heme is metabolized by heme oxygenase-1, which forms biliverdin and carbon monoxide and releases iron. Biliverdin is subsequently converted to bilirubin. It has been argued that heme oxygenase may have both pro- and anti-oxidant effects in the cell.160,166 Release of redox active iron may increase the formation of ROS, and carbon monoxide inhibits Complex IV in a manner that increases ROS.167 On the other hand, bilirubin is an antioxidant and carbon dioxide has vasodilator properties that mimic the generally favorable effects of nitric oxide via activation of guanylyl cyclase.168 Heme oxygenase expression is induced by AMPK via the transcription factor NRF-2.169 A recent study showed that endothelial-selective constitutive activation of AMPK prevented the development of endothelial dysfunction in a heme oxygenase-dependent manner in a mouse model of diabetes.169 Heme oxygenase also has been shown to have anti-apoptotic effects in endothelial cells.170

Several clinical studies have examined the links between heme metabolism and human cardiovascular disease. For example, patients with diabetes have reduced red blood cell ALA synthase activity.171 A large number of observational studies have shown correlations between heme oxygenase-1 expression in circulating blood cells and coronary artery disease and diabetes mellitus.166 Many of these studies show higher levels of heme oxygenase-1 in patients with risk factors or vascular disease. These findings might implicate heme oxygenase in disease pathogenesis or could represent a compensatory response. It is impossible to distinguish these possibilities or to draw conclusions about the utility of targeting heme oxygenase for therapy, given the observational design of these studies. The specific importance of heme synthesis and heme oxygenase activity for endothelial function has not been directly examined in humans.

Interventions that Improve Mitochondrial Function in the Endothelium

As discussed, a variety of risk factors induce mitochondrial dysfunction in the endothelium, which may contribute to the pathogenesis of atherosclerosis. This observation prompt speculation that interventions that restore mitochondrial function might be protective.172 A list of potential interventions that might affect vascular disease is provided in Table 1. The reader is also referred to the review by Walters and colleagues that focuses on these and other interventions that affect mitochondrial function in the myocardium.73

Table 1
Potential Interventions to Improve Mitochondrial Function in the Endothelium

Mitochondria-directed antioxidants

There is considerable interest in the therapeutic potential of mitochondrial-directed antioxidants. Since mitochondrial-derived ROS are important for signaling, a strategy that reduces ROS to physiological levels, rather than completely eliminates ROS will likely be important.173 One strategy to target mitochondrial ROS is to link antioxidant compounds with a lipophilic cation such as triphenylphosphonium (TPP).172 MitoQ is a TPP-modified ubiquinone that is reduced to ubiquinol within the mitochondria matrix. A similar approach has been used to direct alpha tocopherol or the SOD mimetic tempol to mitochondria.

MitoQ had favorable effects in pre-clinical studies of ischemia-reperfusion injury, sepsis, adriamycin toxicity, and Parkinson’s disease.172 Regarding endothelial function, MitoQ was shown to inhibit oxidative damage and apoptosis in cultured endothelial cells,174 blunt amyloid light chain-induced dysfunction in isolated arterioles,175 and improve endothelial function and lower blood pressure in hypertensive rats.176 Mito-Tempol lowers blood pressure and improves endothelium-dependent vasodilation in mouse models of hypertension.82 Clinical studies have examined MitoQ for the treatment of Parkinson’s disease177 and chronic hepatitis C178 with mixed results. At the present time, it remains unknown whether MitoQ or other TPP-linked compounds will have favorable effects on endothelial function or cardiovascular disease in humans.

Lipoic Acid and Acetyl-L-Carnitine

Lipoic acid is a mitochondrial antioxidant and a coenzyme required for the activity of the Krebs cycle. L-carnitine plays an important role in energy production by conjugating fatty acids for transport into mitochondria. Oral carnitine supplementation in humans is frequently formulated as acetyl-L-carnitine, which enters mitochondria and improves mitochondrial function to a greater extent than L-carnitine.179 In animal models of aging, diabetes mellitus, and hypertension, the combination of lipoic acid and acetyl-L-carnitine, reverses abnormalities of mitochondrial membrane potential, ATP production, and ROS production in a variety of tissues.180 In cultured endothelial cells, lipoic acid improves nitric oxide production, blunts inflammatory activation, and increases the anti-apoptotic protein BCL-2.181183 Dietary supplementation with lipoic acid or acetyl-L-carnitine improves nitric oxide bioavailability and reduces atherosclerosis lesion formation in animal models.184,185

Lipoic acid, L-carnitine, and acetyl-L-carnitine are available over the counter as dietary supplements and their effects of vascular function have been examined. Lipoic acid improves endothelial function in patients with metabolic syndrome or diabetes mellitus, and L-carnitine blunts free fatty acid-induced endothelial dysfunction.186188 It remains unclear, however, whether the beneficial effects of these compounds on endothelial function can be attributed to an effects on mitochondrial function.

Interventions that Activate AMPK and PGC-1α

Interventions that increase the activity of AMPK and PGC-1α have been consistently shown to improve endothelial function in animals. For example, short-term calorie restriction reverses endothelial dysfunction and oxidative stress in old mice.189 Calorie restriction also promotes mitochondrial biogenesis and increases expression of MnSOD.189,190 The glycolysis inhibitor 2-deoxyglucose activates AMPK, induces autophagy, and protects against cell death in cultured endothelial cells.52 The thiazolidinediones, including pioglitazone, have also been reported to activate PGC-1α and increase mitochondrial biogenesis in endothelial cells.191 Metformin, which activates AMPK, has been shown to inhibit MPT pore opening and endothelial apoptosis and to prevent the development of endothelial dysfunction in experimental models.17,147

In regard to clinical studies, it is well established that exercise and weight loss improve endothelial vasodilator function in patients with obesity, diabetes, and other risk factors.1 A weight loss and exercise program increased expression of PGC-1α in skeletal muscle of elderly women.59 Metformin reverses endothelial dysfunction in patients with diabetes mellitus,192 although it remains unclear whether metformin actually activates AMPK in vivo. Given the many favorable effects of these interventions on risk factors and metabolism, it remains unknown whether improved endothelial function reflects altered mitochondrial function.

Sirtuins

The sirtuins play important roles in the regulation of lifespan and metabolism with implications for mitochondrial function and may be targets for therapy, as was recently reviewed.193,194 Sirtuins regulate gene expression and enzyme activity via their activity as NAD+-dependent deacetylases. Sirtuin 1 (SIRT1) deacetylates and activates PGC-1α, leading to favorable effects on glucose and lipid metabolism and expression of mitochondrial genes.193,195197 SIRT3 is specifically localized to the mitochondrial matrix and controls mitochondrial energetics by deacetylating mitochondrial enzymes.193,198 Interestingly, SIRT3 also deacetylates and activates MnSOD and thus may reduce mitochondrial superoxide levels.199

In regard to the cardiovascular system, there is extensive evidence that SIRT1 has protective effects against ischemic injury and hypertrophy in the heart.193 SIRT1 is known to deacetylate and activate eNOS in the endothelium and to regulate angiogenesis.193,200,201 In regard to clinical studies, SIRT1 expression is reduced in endothelial cells isolated from the brachial artery and correlates with endothelium-dependent vasodilation in elderly human subjects.202

There is limited evidence that the mitochondrial SIRT3 may have favorable effects in endothelial cells, although it is unclear whether such effects are mediated through alterations in mitochondrial function. For example, endothelial-specific inhibition of NF-κB in a mouse model is associated with reduced inflammation, improved insulin sensitivity, enhanced mitochondrial biogenesis, improved blood flow, and increased lifespan.203 In vascular tissue from these animals, there is upregulation of SIRT3.203 In humans, aging is associated with reduced expression of SIRT3 in skeletal muscle of sedentary, but not endurance-trained individuals. To date, the effects of specific SIRT3 activation on endothelial function have not been examined in experimental models or human subjects. However, there is currently great interest in the possibility that activators of SIRT1 and SIRT3 will have benefit against metabolic and cardiovascular disease.194

Resveratrol

Resveratrol (3,4',5-trihydroxystilbene) is a polyphenolic compound found in a variety of foods, including grapes and red wine. Initial experimental studies reported that resveratrol activates SIRT1.204 More recent evidence suggests that the beneficial effects of resveratrol also involve activation of AMPK.205 In animal models, resveratrol mimics the beneficial effects of calorie restriction on insulin sensitivity, mitochondrial biogenesis, and longevity.204

Resveratrol induces mitochondrial biogenesis in endothelial cells by increasing PGC-1α and NRF-1 in a manner that depends on SIRT1 and eNOS activation and has similar effects in the aorta of diabetic (db/db) mice.206 In endothelial cells, resveratrol has antioxidant effects and has been shown to increase the expression of MnSOD and reduce cellular hydrogen peroxide levels.207 Furthermore, resveratrol has cytoprotective properties and prevents induction of apoptosis in the setting of oxidative stress by upregulation of BCL-2.208 This constellation of atheroprotective effects has generated significant interest for therapeutic applications. In obese humans, oral resveratrol treatment was shown to acutely improve endothelium-dependent vasodilation.209 A number of other ongoing clinical trials are examining resveratrol treatment for metabolic and vascular endpoints, but to date, the effects of long-term resveratrol treatment on vascular function, mitochondrial function, or cardiovascular disease remain unknown.

Inhibition of Mitochondrial Fission

Clinical studies suggest that diabetes mellitus and other pathological states are associated with increased mitochondrial fission and impaired autophagy in the endothelium.39,56 Mitochondrial division inhibitor-1 (Mdivi-1) is an inhibitor of the fission protein DRP 1 and has been shown to decrease mitochondrial outer membrane permeabilization, cytochrome c release, and apoptotic cell death.210 Mdivi-1 has also been shown to limit ischemia reperfusion injury in isolated myocytes and to reduce infarct size in a mouse model.211 The effects of this compound on endothelial function are unknown.

Mitochondrial Membrane Depolarizing Agents

Uncoupling proteins, including UCP2, act to induce mild membrane depolarization and reduce mitochondrial ROS production.104 Overexpression of UCP2 improves endothelial function in a rat model, 109 suggesting that an uncoupling agent might have therapeutic potential. In arterioles isolated from patients with diabetes mellitus, the uncoupling agent carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) lowers membrane potential and improves endothelial function.26 2,4-Dinitrophenol is another uncoupling agent that has been used in humans for the treatment of obesity.172 Clinical trials with this compound were stopped due to high toxicity, but it remains possible that less potent, self-limiting uncoupling agents might prove useful mitochondria-directed therapeutics.172

Micro RNA’s

There is recent appreciation of the importance of micro-RNAs in the coordination of many biological processes.212 In pulmonary endothelial cells, micro-RNA-210 (miR-210) has been identified as a repressor of iron-sulfur cluster assembly proteins (ISCU1/2), which are important for the expression of components of the electron transport chain and Krebs cycle.213 Under conditions of hypoxia and activation of HIF-1α, miR-210 is upregulated, thereby repressing mitochondrial iron-sulfur enzymes and mitochondrial respiration in endothelial cells. This response may be important for the Pasteur effect and the mammalian adaptation to hypoxia.213 Given the recent interest in micro-RNA’s as therapeutic targets,212 these results suggest that targeting miR-210 might be an approach to broadly regulate mitochondrial respiration and endothelial function.

Conclusions

This article reviews key aspects of mitochondrial function in the endothelium. Mitochondria content in endothelial cells is relatively modest, and subcellular location relative to the nucleus, cytoskeletal elements, calcium channels, and the ER is important for ROS and calcium signaling. In addition to regulating biogenesis, PGC-1α orchestrates a cellular response to oxidative stress by increasing the expression of mitochondrial antioxidant enzymes and uncoupling proteins. Mitochondrial quality control mechanisms, including mitochondrial dynamics and autophagy/mitophagy are needed for normal angiogenic and vasodilator function of endothelial cells. Mitochondrial-ROS are important for signaling physiological responses to nutrient status, hypoxia, and shear stress. An array of antioxidant enzymes, uncoupling proteins, and other mechanisms in mitochondrial combine to modulate and direct ROS signals. Mitochondria interact with the ER to regulate calcium signaling, which is essential for key aspects of endothelial function including eNOS activation, motility, barrier function, and angiogenesis. In general, physiological ROS and calcium signaling activates short or long-term functional changes in endothelial cells to maintain blood flow to tissues through control of vascular tone and angiogenesis. Physiological ROS signaling that promotes inflammation is important for normal immune function. Such signals are also involved in regulated cell death pathways, which eliminate senescent and irreversibly damaged cells. Excessive ROS and disordered calcium signaling, however, contribute to the pathogenesis of vascular disease. Finally, we reviewed the importance of mitochondria in heme synthesis and metabolism, which in addition to generating heme for use as an enzymatic cofactor, may be emerging as another aspect of mitochondrial function that regulates cellular redox state in the endothelium.

While a large body of experimental work has shown that mitochondria are important for endothelial function, only a relatively small number of translational studies have shown the clinical relevance of these mechanisms in humans (Table 2). As described, studies of isolated vascular tissue and endothelial cells from diabetic and elderly humans indicate the importance of subcellular location, biogenesis, dynamics, autophagy, and pathological ROS levels. Only a very few studies have investigated the signaling aspects of ROS and calcium, and little is known about the specific importance of endothelial PGC-1α, regulated cell death, and heme metabolism in humans. Epidemiological studies have shown correlations between human disease and polymorphisms of genes related to mitochondrial function. Blood markers of mitochondrial dysfunction, such as mtDNA damage and assessment of mitochondrial oxygen consumption in circulating leukocytes or platelets may facilitate studies of systemic abnormalities of mitochondrial function and their relation to cardiovascular disease. The presented studies suggest that mitochondria-directed therapies have potential for the prevention and management of cardiovascular vascular disease, in part by improving mitochondrial function in the endothelium.

Table 2
Translational Methods for Study of Mitochondria and Endothelial Function in Humans

Supplementary Material

Acknowledgments

Sources of Funding

Dr. Fetterman receives support from T32 HL007224. Dr. Vita’s work is supported by NIH grants HL081587, HL083801, HL102299, and HL083781 from the National Heart, Lung and Blood Institute.

Nonstandard Abbreviations

ALA
Amino levulinic acid
AMPK
AMP-activated protein kinase
ApoE
Apolipoprotein E
ATG
Autophagy-related protein
DRP1
Dynamin-related protein-1
eNOS
Endothelial nitric oxide synthase
ER
Endoplasmic reticulum
FIS1
Fission 1
LC3
microtubule-associated protein 1 light chain 3
MAO
Monoamine oxidase
Mdivi-1
Mitochondrial division inhibitor-1
miR
MicroRNA
MnSOD
Manganese superoxide dismutase
MPT
Mitochondrial permeability transition
mtDNA
Mitochondrial DNA
NF-κB
Nuclear factor-κB
NO
Nitric oxide
NOX4
NADPH oxidase 4
NRF
Nuclear respiratory factor
OPA1
Optic atrophy protein 1
PGC-1α
Peroxisome proliferator-activated receptor gamma coactivator-1 alpha
ROS
Reactive oxygen species
SIRT1/3
Sirtuin 1/3
TFAM
Transcription factor A, mitochondrial
TNF-α
Tissue necrosis factor-alpha
TPP
Triphenylphosphonium
TRX2
Thioredoxin 2
UCP1/2/3
Uncoupling protein 1/2/3

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures

None.

References

1. Widlansky ME, Gokce N, Keaney JF, Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–1160. [PubMed]
2. Culic O, Gruwel ML, Schrader J. Energy turnover of vascular endothelial cells. Am J Physiol. 1997;273:C205–C213. [PubMed]
3. Darley-Usmar V. The powerhouse takes control of the cell; the role of mitochondria in signal transduction. Free Radic Biol Med. 2004;37:753–754. [PubMed]
4. Widlansky ME, Gutterman DD. Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxid Redox Signal. 2011 [PMC free article] [PubMed]
5. Barth E, Stammler G, Speiser B, Schaper J. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol. 1992;24:669–681. [PubMed]
6. Oldendorf WH, Cornford ME, Brown WJ. The large apparent work capability of the blood-brain barrier: a study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann Neurol. 1977;1:409–417. [PubMed]
7. Park J, Lee J, Choi C. Mitochondrial network determines intracellular ROS dynamics and sensitivity to oxidative stress through switching inter-mitochondrial messengers. PLoS One. 2011;6:e23211. [PMC free article] [PubMed]
8. Al-Mehdi AB, Pastukh VM, Swiger BM, Reed DJ, Patel MR, Bardwell GC, Pastukh VV, Alexeyev MF, Gillespie MN. Perinuclear mitochondrial clustering creates an oxidant-rich nuclear domain required for hypoxia-induced transcription. Sci Signal. 2012;5 ra47. [PMC free article] [PubMed]
9. Liu Y, Li H, Bubolz AH, Zhang DX, Gutterman DD. Endothelial cytoskeletal elements are critical for flow-mediated dilation in human coronary arterioles. Med Biol Eng Comput. 2008;46:469–478. [PMC free article] [PubMed]
10. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R, Valerio A, Francolini M, Moncada S, Carruba MO. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science. 2003;299:896–899. [PubMed]
11. Patten IS, Arany Z. PGC-1 coactivators in the cardiovascular system. Trends Endocrinol Metab. 2012;23:90–97. [PubMed]
12. Dominy JE, Jr, Lee Y, Gerhart-Hines Z, Puigserver P. Nutrient-dependent regulation of PGC-1alpha's acetylation state and metabolic function through the enzymatic activities of Sirt1/GCN5. Biochim Biophys Acta. 2010;1804:1676–1683. [PMC free article] [PubMed]
13. Leone TC, Kelly DP. Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb Symp Quant Biol. 2011;76:175–182. [PMC free article] [PubMed]
14. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451:1008–1012. [PubMed]
15. Riehle C, Wende AR, Zaha VG, Pires KM, Wayment B, Olsen C, Bugger H, Buchanan J, Wang X, Moreira AB, Doenst T, Medina-Gomez G, Litwin SE, Lelliott CJ, Vidal-Puig A, Abel ED. PGC-1beta deficiency accelerates the transition to heart failure in pressure overload hypertrophy. Circ Res. 2011;109:783–793. [PMC free article] [PubMed]
16. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 2005;66:562–573. [PubMed]
17. Schulz E, Dopheide J, Schuhmacher S, Thomas SR, Chen K, Daiber A, Wenzel P, Munzel T, Keaney JF., Jr. Suppression of the JNK pathway by induction of a metabolic stress response prevents vascular injury and dysfunction. Circulation. 2008;118:1347–1357. [PMC free article] [PubMed]
18. Twig G, Hyde B, Shirihai OS. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta. 2008;1777:1092–1097. [PMC free article] [PubMed]
19. Stein S, Lohmann C, Handschin C, Stenfeldt E, Boren J, Luscher TF, Matter CM. ApoE−/− PGC-1alpha−/− mice display reduced IL-18 levels and do not develop enhanced atherosclerosis. PLoS One. 2010;5:e13539. [PMC free article] [PubMed]
20. Mitra R, Nogee DP, Zechner JF, Yea K, Gierasch CM, Kovacs A, Medeiros DM, Kelly DP, Duncan JG. The transcriptional coactivators, PGC-1alpha and beta, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol. 2012;52:701–710. [PMC free article] [PubMed]
21. Li C, Cai S, Keaney JF., Jr. Mitochondrial regulation of endothelial function. Circulation. 2012;126:A16000.
22. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51:2944–2950. [PubMed]
23. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–273. [PubMed]
24. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664–671. [PMC free article] [PubMed]
25. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, Dweik RA, Tuder RM, Stuehr DJ, Erzurum SC. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 2007;104:1342–1347. [PubMed]
26. Kizhakekuttu TJ, Wang J, Dharmashankar K, Ying R, Gutterman DD, Vita JA, Widlansky ME. Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2012;32:2531–2539. [PMC free article] [PubMed]
27. Oberkofler H, Holzl B, Esterbauer H, Xie M, Iglseder B, Krempler F, Paulweber B, Patsch W. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension. 2003;41:368–372. [PubMed]
28. Iglseder B, Oberkofler H, Felder TK, Klein K, Paulweber B, Krempler F, Tregouet DA, Patsch W. Associations of PPARGC1A haplotypes with plaque score but not with intima-media thickness of carotid arteries in middle-aged subjects. Stroke. 2006;37:2260–2265. [PubMed]
29. Zhang Y, Xu W, Li X, Tang Y, Xie P, Ji Y, Fan L, Chen Q. Association between PPARGC1A gene polymorphisms and coronary artery disease in a Chinese population. Clin Exp Pharmacol Physiol. 2008;35:1172–1177. [PubMed]
30. Kitami T, Logan DJ, Negri J, Hasaka T, Tolliday NJ, Carpenter AE, Spiegelman BM, Mootha VK. A chemical screen probing the relationship between mitochondrial content and cell size. PLoS One. 2012;7:e33755. [PMC free article] [PubMed]
31. Chen Y, Liu Y, Dorn GW. Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ Res. 2011;109:1327–1331. [PMC free article] [PubMed]
32. Suen DF, Norris KL, Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev. 2008;22:1577–1590. [PubMed]
33. Yoon Y, Krueger EW, Oswald BJ, McNiven MA. The mitochondrial protein hFis1 regulates mitochondrial fission in mammalian cells through an interaction with the dynamin-like protein DLP1. Mol Cell Biol. 2003;23:5409–5420. [PMC free article] [PubMed]
34. Cribbs JT, Strack S. Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep. 2007;8:939–944. [PubMed]
35. Landes T, Martinou JC. Mitochondrial outer membrane permeabilization during apoptosis: the role of mitochondrial fission. Biochim Biophys Acta. 2011;1813:540–545. [PubMed]
36. Lugus JJ, Ngoh GA, Bachschmid MM, Walsh K. Mitofusins are required for angiogenic function and modulate different signaling pathways in cultured endothelial cells. J Mol Cell Cardiol. 2011;51:885–893. [PMC free article] [PubMed]
37. Jendrach M, Mai S, Pohl S, Voth M, Bereiter-Hahn J. Short- and long-term alterations of mitochondrial morphology, dynamics and mtDNA after transient oxidative stress. Mitochondrion. 2008;8:293–304. [PubMed]
38. Paltauf-Doburzynska J, Malli R, Graier WF. Hyperglycemic conditions affect shape and Ca2+ homeostasis of mitochondria in endothelial cells. J Cardiovasc Pharmacol. 2004;44:423–436. [PubMed]
39. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, Tabit CE, Hamburg NM, Frame AA, Caiano TL, Kluge MA, Duess MA, Levit A, Kim B, Hartman ML, Joseph L, Shirihai OS, Vita JA. Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation. 2011;124:444–453. [PMC free article] [PubMed]
40. Giedt RJ, Yang C, Zweier JL, Matzavinos A, Alevriadou BR. Mitochondrial fission in endothelial cells after simulated ischemia/reperfusion: role of nitric oxide and reactive oxygen species. Free Radic Biol Med. 2012;52:348–356. [PMC free article] [PubMed]
41. Wang Z, Liu Y, Liu J, Liu K, Wen J, Wen S, Wu Z. HSG/Mfn2 gene polymorphism and essential hypertension: a case-control association study in Chinese. J Atheroscler Thromb. 2011;18:24–31. [PubMed]
42. Jin HS, Sober S, Hong KW, Org E, Kim BY, Laan M, Oh B, Jeong SY. Age-dependent association of the polymorphisms in the mitochondria-shaping gene, OPA1, with blood pressure and hypertension in Korean population. Am J Hypertens. 2011;24:1127–1135. [PubMed]
43. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12:9–14. [PubMed]
44. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science. 2011;333:1109–1112. [PMC free article] [PubMed]
45. Choi AM, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med. 2013;368:651–662. [PubMed]
46. Kubli DA, Gustafsson AB. Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res. 2012;111:1208–1221. [PMC free article] [PubMed]
47. Mai S, Muster B, Bereiter-Hahn J, Jendrach M. Autophagy proteins LC3B, ATG5 and ATG12 participate in quality control after mitochondrial damage and influence lifespan. Autophagy. 2012;8 [PMC free article] [PubMed]
48. Madeo F, Tavernarakis N, Kroemer G. Can autophagy promote longevity? Nat Cell Biol. 2010;12:842–846. [PubMed]
49. Rifki OF, Hill JA. Cardiac autophagy: good with the bad. J Cardiovasc Pharmacol. 2012;60:248–252. [PMC free article] [PubMed]
50. Razani B, Feng C, Coleman T, Emanuel R, Wen H, Hwang S, Ting JP, Virgin HW, Kastan MB, Semenkovich CF. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab. 2012;15:534–544. [PMC free article] [PubMed]
51. Khan MJ, Rizwan AM, Waldeck-Weiermair M, Karsten F, Groschner L, Riederer M, Hallstrom S, Rockenfeller P, Konya V, Heinemann A, Madeo F, Graier WF, Malli R. Inhibition of autophagy rescues palmitic acid-induced necroptosis of endothelial cells. J Biol Chem. 2012;287:21110–21120. [PMC free article] [PubMed]
52. Wang Q, Liang B, Shirwany NA, Zou MH. 2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. PLoS One. 2011;6:e17234. [PMC free article] [PubMed]
53. Higdon AN, Benavides GA, Chacko BK, Ouyang X, Johnson MS, Landar A, Zhang J, Darley-Usmar VM. Hemin causes mitochondrial dysfunction in endothelial cells through promoting lipid peroxidation: The protective role of autophagy. Am J Physiol Heart Circ Physiol. 2012;302:H1394–H1409. [PubMed]
54. Zhang YL, Cao YJ, Zhang X, Liu HH, Tong T, Xiao GD, Yang YP, Liu CF. The autophagy-lysosome pathway: a novel mechanism involved in the processing of oxidized LDL in human vascular endothelial cells. Biochem Biophys Res Commun. 2010;394:377–382. [PubMed]
55. Mai S, Klinkenberg M, Auburger G, Bereiter-Hahn J, Jendrach M. Decreased expression of Drp1 and Fis1 mediates mitochondrial elongation in senescent cells and enhances resistance to oxidative stress through PINK1. J Cell Sci. 2010;123:917–926. [PubMed]
56. Larocca TJ, Henson GD, Thorburn A, Sindler AL, Pierce GL, Seals DR. Translational evidence that impaired autophagy contributes to arterial ageing. J Physiol. 2012;590:3305–3316. [PubMed]
57. Kassiotis C, Ballal K, Wellnitz K, Vela D, Gong M, Salazar R, Frazier OH, Taegtmeyer H. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation. 2009;120:S191–S197. [PMC free article] [PubMed]
58. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, An Z, Loh J, Fisher J, Sun Q, Korsmeyer S, Packer M, May HI, Hill JA, Virgin HW, Gilpin C, Xiao G, Bassel-Duby R, Scherer PE, Levine B. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature. 2012;481:511–515. [PMC free article] [PubMed]
59. Wohlgemuth SE, Lees HA, Marzetti E, Manini TM, Aranda JM, Daniels MJ, Pahor M, Perri MG, Leeuwenburgh C, Anton SD. An exploratory analysis of the effects of a weight loss plus exercise program on cellular quality control mechanisms in older overweight women. Rejuvenation Res. 2011;14:315–324. [PMC free article] [PubMed]
60. Chance B, Sies H, Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev. 1979;59:527–605. [PubMed]
61. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13. [PMC free article] [PubMed]
62. Chen F, Haigh S, Barman S, Fulton DJ. From form to function: the role of Nox4 in the cardiovascular system. Front Physiol. 2012;3:412. [PMC free article] [PubMed]
63. Lassegue B, San Martin A, Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110:1364–1390. [PMC free article] [PubMed]
64. Kaludercic N, Takimoto E, Nagayama T, Feng N, Lai EW, Bedja D, Chen K, Gabrielson KL, Blakely RD, Shih JC, Pacak K, Kass DA, Di Lisa F, Paolocci N. Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. Circ Res. 2010;106:193–202. [PMC free article] [PubMed]
65. Poon CC, Seto SW, Au AL, Zhang Q, Li RW, Lee WY, Leung GP, Kong SK, Yeung JH, Ngai SM, Ho HP, Lee SM, Chan SW, Kwan YW. Mitochondrial monoamine oxidase-A-mediated hydrogen peroxide generation enhances 5-hydroxytryptamine-induced contraction of rat basilar artery. Br J Pharmacol. 2010;161:1086–1098. [PMC free article] [PubMed]
66. Meresse S, Dehouck MP, Delorme P, Bensaid M, Tauber JP, Delbart C, Fruchart JC, Cecchelli R. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J Neurochem. 1989;53:1363–1371. [PubMed]
67. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 2005;122:221–233. [PubMed]
68. Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, Luscher TF, Cosentino F. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res. 2012;111:278–289. [PubMed]
69. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, Pelicci P, Volpe M, Anversa P, Luscher TF, Cosentino F. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A. 2007;104:5217–5222. [PubMed]
70. Trinei M, Berniakovich I, Beltrami E, Migliaccio E, Fassina A, Pelicci P, Giorgio M. P66Shc signals to age. Aging (Albany NY) 2009;1:503–510. [PMC free article] [PubMed]
71. Foster DB, Ho AS, Rucker J, Garlid AO, Chen L, Sidor A, Garlid KD, O'Rourke B. Mitochondrial ROMK channel is a molecular component of mitoK(ATP) Circ Res. 2012;111:446–454. [PMC free article] [PubMed]
72. Queliconi BB, Wojtovich AP, Nadtochiy SM, Kowaltowski AJ, Brookes PS. Redox regulation of the mitochondrial K(ATP) channel in cardioprotection. Biochim Biophys Acta. 2011;1813:1309–1315. [PMC free article] [PubMed]
73. Walters AM, Porter GA, Jr., Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res. 2012;111:1222–1236. [PMC free article] [PubMed]
74. Feng J, Zuo Z. Isoflurane preconditioning increases endothelial cell tolerance to in-vitro simulated ischaemia. J Pharm Pharmacol. 2011;63:106–110. [PMC free article] [PubMed]
75. Beresewicz A, Maczewski M, Duda M. Effect of classic preconditioning and diazoxide on endothelial function and O2- and NO generation in the post-ischemic guinea-pig heart. Cardiovasc Res. 2004;63:118–129. [PubMed]
76. Huang Q, Guo Z, Yu Y, Ghatnekar GS, Ghatnekar AV, Bu M, Guo X, Liu S, Wang F, Feng Z, Bu S. Diazoxide inhibits aortic endothelial cell apoptosis in diabetic rats via activation of ERK. Acta Diabetol. 2012;49:205–214. [PubMed]
77. Broadhead MW, Kharbanda RK, Peters MJ, MacAllister RJ. KATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo. Circulation. 2004;110:2077–2082. [PubMed]
78. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, Cole TJ, Yellon DM, Deanfield JE, MacAllister RJ. Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation. 2007;116:1386–1395. [PubMed]
79. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta. 2006;1757:509–517. [PubMed]
80. Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta. 2010;1797:897–906. [PubMed]
81. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488–496. [PubMed]
82. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 2010;107:106–116. [PMC free article] [PubMed]
83. Stocker R, Keaney JF., Jr Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–1478. [PubMed]
84. Richardson RS, Donato AJ, Uberoi A, Wray DW, Lawrenson L, Nishiyama S, Bailey DM. Exercise-induced brachial artery vasodilation: role of free radicals. Am J Physiol Heart Circ Physiol. 2007;292:H1516–H1522. [PubMed]
85. Phillips SA, Hatoum OA, Gutterman DD. The mechanism of flow-induced dilation in human adipose arterioles involves hydrogen peroxide during CAD. Am J Physiol Heart Circ Physiol. 2007;292:H93–H100. [PubMed]
86. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37:117–123. [PubMed]
87. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. [PubMed]
88. Algahim MF, Sen S, Taegtmeyer H. Bariatric surgery to unload the stressed heart: a metabolic hypothesis. Am J Physiol Heart Circ Physiol. 2012;302:H1539–H1545. [PubMed]
89. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev. 2010;90:207–258. [PubMed]
90. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–790. [PubMed]
91. Hill BG, Benavides GA, Lancaster JR, Ballinger S, Dell'italia L, Zhang J, Darley-Usmar VM. Integration of cellular bioenergetics with mitochondrial quality control and autophagy. Biol Chem. 2012 [PMC free article] [PubMed]
92. Ballinger SW, Patterson C, Yan CN, Doan R, Burow DL, Young CG, Yakes FM, Van HB, Ballinger CA, Freeman BA, Runge MS. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res. 2000;86:960–966. [PubMed]
93. Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, Ischiropoulos H, Ballinger SW. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105:849–854. [PubMed]
94. Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, Reuf J, Horaist C, Lebovitz R, Hunter GC, McIntyre K, Runge MS. Mitochondrial integrity and function in atherogenesis. Circulation. 2002;106:544–549. [PubMed]
95. Pun PB, Murphy MP. Pathological significance of mitochondrial glycation. Int J Cell Biol. 2012;2012:843505. [PMC free article] [PubMed]
96. Widlansky ME, Wang J, Shenouda SM, Hagen TM, Smith AR, Kizhakekuttu TJ, Kluge MA, Weihrauch D, Gutterman DD, Vita JA. Altered mitochondrial membrane potential, mass, and morphology in the mononuclear cells of humans with type 2 diabetes. Transl Res. 2010;156:15–25. [PMC free article] [PubMed]
97. Wang J, Alexanian A, Ying R, Kizhakekuttu TJ, Dharmashankar K, Vasquez-Vivar J, Gutterman DD, Widlansky ME. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: Role for AMP kinase. Arterioscler Thromb Vasc Biol. 2012;32:712–720. [PMC free article] [PubMed]
98. Liu C, Yang Q, Hwang SJ, Sun F, Johnson AD, Shirihai OS, Vasan RS, Levy D, Schwartz F. Association of genetic variation in the mitochondrial genome with blood pressure and metabolic traits. Hypertension. 2012;60:949–956. [PMC free article] [PubMed]
99. Bengtsson B, Thulin T, Schersten B. Familial resemblance in casual blood pressure--a maternal effect? Clin Sci (Lond) 1979;57(Suppl 5):279s–281s. [PubMed]
100. Brown KA, Didion SP, Andresen JJ, Faraci FM. Effect of aging, MnSOD deficiency, and genetic background on endothelial function: evidence for MnSOD haploinsufficiency. Arterioscler Thromb Vasc Biol. 2007;27:1941–1946. [PubMed]
101. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912–1916. [PubMed]
102. Forgione MA, Cap A, Liao R, Moldovan NI, Eberhardt RT, Lim CC, Jones J, Goldschmidt-Clermont PJ, Loscalzo J. Heterozygous cellular glutathione peroxidase deficiency in the mouse: abnormalities in vascular and cardiac function and structure. Circulation. 2002;106:1154–1158. [PubMed]
103. Widder JD, Fraccarollo D, Galuppo P, Hansen JM, Jones DP, Ertl G, Bauersachs J. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension. 2009;54:338–344. [PMC free article] [PubMed]
104. Duval C, Negre-Salvayre A, Dogilo A, Salvayre R, Penicaud L, Casteilla L. Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells. Biochem Cell Biol. 2002;80:757–764. [PubMed]
105. Mailloux RJ, Harper ME. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radic Biol Med. 2011;51:1106–1115. [PubMed]
106. Echtay KS, Roussel D, St Pierre J, Jekabsons MB, Cadenas S, Stuart JA, Harper JA, Roebuck SJ, Morrison A, Pickering S, Clapham JC, Brand MD. Superoxide activates mitochondrial uncoupling proteins. Nature. 2002;415:96–99. [PubMed]
107. Echtay KS, Esteves TC, Pakay JL, Jekabsons MB, Lambert AJ, Portero-Otin M, Pamplona R, Vidal-Puig AJ, Wang S, Roebuck SJ, Brand MD. A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling. EMBO J. 2003;22:4103–4110. [PubMed]
108. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res. 2010;88:229–240. [PMC free article] [PubMed]
109. Lee KU, Lee IK, Han J, Song DK, Kim YM, Song HS, Kim HS, Lee WJ, Koh EH, Song KH, Han SM, Kim MS, Park IS, Park JY. Effects of recombinant adenovirus-mediated uncoupling protein 2 overexpression on endothelial function and apoptosis. Circ Res. 2005;96:1200–1207. [PubMed]
110. Moukdar F, Robidoux J, Lyght O, Pi J, Daniel KW, Collins S. Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice. J Lipid Res. 2009;50:59–70. [PubMed]
111. Tian XY, Wong WT, Xu A, Lu Y, Zhang Y, Wang L, Cheang WS, Wang Y, Yao X, Huang Y. Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res. 2012;110:1211–1216. [PubMed]
112. Haines BA, Mehta SL, Pratt SM, Warden CH, Li PA. Deletion of mitochondrial uncoupling protein-2 increases ischemic brain damage after transient focal ischemia by altering gene expression patterns and enhancing inflammatory cytokines. J Cereb Blood Flow Metab. 2010;30:1825–1833. [PMC free article] [PubMed]
113. Cheurfa N, Dubois-Laforgue D, Ferrarezi DA, Reis AF, Brenner GM, Bouche C, Le Feuvre C, Fumeron F, Timsit J, Marre M, Velho G. The common −866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men. Diabetes. 2008;57:1063–1068. [PubMed]
114. Oberkofler H, Iglseder B, Klein K, Unger J, Haltmayer M, Krempler F, Paulweber B, Patsch W. Associations of the UCP2 gene locus with asymptomatic carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2005;25:604–610. [PubMed]
115. Zee RY, Ridker PM, Chasman DI. Mitochondrial uncoupling protein gene cluster variation (UCP2-UCP3) and the risk of incident type 2 diabetes mellitus: the Women's Genome Health Study. Atherosclerosis. 2011;214:107–109. [PMC free article] [PubMed]
116. Erusalimsky JD, Moncada S. Nitric oxide and mitochondrial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:2524–2531. [PubMed]
117. Dranka BP, Hill BG, Darley-Usmar VM. Mitochondrial reserve capacity in endothelial cells: The impact of nitric oxide and reactive oxygen species. Free Radic Biol Med. 2010;48:905–914. [PMC free article] [PubMed]
118. Millan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry. 1998;37:1613–1622. [PubMed]
119. Sessa WC. Regulation of endothelial derived nitric oxide in health and disease. Mem Inst Oswaldo Cruz. 2005;100(Suppl 1):15–18. [PubMed]
120. Cai H, Liu D, Garcia JG. CaM Kinase II-dependent pathophysiological signalling in endothelial cells. Cardiovasc Res. 2008;77:30–34. [PubMed]
121. Andrikopoulos P, Baba A, Matsuda T, Djamgoz MB, Yaqoob MM, Eccles SA. Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells. J Biol Chem. 2011;286:37919–37931. [PubMed]
122. Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ, Camello PJ. Mitochondrial reactive oxygen species and Ca2+ signaling. Am J Physiol Cell Physiol. 2006;291:C1082–C1088. [PubMed]
123. Davidson SM, Duchen MR. Endothelial mitochondria: contributing to vascular function and disease. Circ Res. 2007;100:1128–1141. [PubMed]
124. Szabadkai G, Duchen MR. Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda) 2008;23:84–94. [PubMed]
125. Groschner LN, Waldeck-Weiermair M, Malli R, Graier WF. Endothelial mitochondria--less respiration, more integration. Pflugers Arch. 2012;464:63–76. [PMC free article] [PubMed]
126. Malli R, Frieden M, Trenker M, Graier WF. The role of mitochondria for Ca2+ refilling of the endoplasmic reticulum. J Biol Chem. 2005;280:12114–12122. [PubMed]
127. Rizzuto R, Pozzan T. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev. 2006;86:369–408. [PubMed]
128. Jornot L, Maechler P, Wollheim CB, Junod AF. Reactive oxygen metabolites increase mitochondrial calcium in endothelial cells: implication of the Ca2+/Na+ exchanger. J Cell Sci. 1999;112(Pt 7):1013–1022. [PubMed]
129. Raturi A, Simmen T. Where the endoplasmic reticulum and the mitochondrion tie the knot: The mitochondria-associated membrane (MAM) Biochim Biophys Acta. 2013;1833:213–224. [PubMed]
130. Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, Michelakis ED. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med. 2011;3:88ra55. [PMC free article] [PubMed]
131. Liu X, Hajnoczky G. Ca2+-dependent regulation of mitochondrial dynamics by the Miro-Milton complex. Int J Biochem Cell Biol. 2009;41:1972–1976. [PMC free article] [PubMed]
132. Rowlands DJ, Islam MN, Das SR, Huertas A, Quadri SK, Horiuchi K, Inamdar N, Emin MT, Lindert J, Ten VS, Bhattacharya S, Bhattacharya J. Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+ determines the severity of inflammation in mouse lung microvessels. J Clin Invest. 2011;121:1986–1999. [PMC free article] [PubMed]
133. Bubolz AH, Mendoza SA, Zheng X, Zinkevich NS, Li R, Gutterman DD, Zhang DX. Activation of endothelial TRPV4 channels mediates flow-induced dilation in human coronary arterioles: role of Ca2+ entry and mitochondrial ROS signaling. Am J Physiol Heart Circ Physiol. 2012;302:H634–H642. [PubMed]
134. Gottlieb RA. Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther. 2011;16:233–238. [PMC free article] [PubMed]
135. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res. 2011;108:1017–1036. [PubMed]
136. Vandenabeele P, Galluzzi L, Vanden BT, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11:700–714. [PubMed]
137. Wang Z, Jiang H, Chen S, Du F, Wang X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell. 2012;148:228–243. [PubMed]
138. Davis CW, Hawkins BJ, Ramasamy S, Irrinki KM, Cameron BA, Islam K, Daswani VP, Doonan PJ, Manevich Y, Madesh M. Nitration of the mitochondrial complex I subunit NDUFB8 elicits RIP1- and RIP3-mediated necrosis. Free Radic Biol Med. 2010;48:306–317. [PMC free article] [PubMed]
139. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516. [PMC free article] [PubMed]
140. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59. [PubMed]
141. Galluzzi L, Kepp O, Trojel-Hansen C, Kroemer G. Mitochondrial control of cellular life, stress, and death. Circ Res. 2012;111:1198–1207. [PubMed]
142. Brooks C, Wei Q, Feng L, Dong G, Tao Y, Mei L, Xie ZJ, Dong Z. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci U S A. 2007;104:11649–11654. [PubMed]
143. Brenner C, Moulin M. Physiological roles of the permeability transition pore. Circ Res. 2012;111:1237–1247. [PubMed]
144. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol. 2007;9:550–555. [PMC free article] [PubMed]
145. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658–662. [PubMed]
146. Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic Biol Med. 1999;27:752–763. [PubMed]
147. Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N, Leverve X. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54:2179–2187. [PubMed]
148. Trudeau K, Muto T, Roy S. Downregulation of mitochondrial connexin 43 by high glucose triggers mitochondrial shape change and cytochrome C release in retinal endothelial cells. Invest Ophthalmol Vis Sci. 2012;53:6675–6681. [PMC free article] [PubMed]
149. Rodriguez-Sinovas A, Boengler K, Cabestrero A, Gres P, Morente M, Ruiz-Meana M, Konietzka I, Miro E, Totzeck A, Heusch G, Schulz R, Garcia-Dorado D. Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ Res. 2006;99:93–101. [PubMed]
150. Baines CP. The cardiac mitochondrion: nexus of stress. Annu Rev Physiol. 2010;72:61–80. [PubMed]
151. Wang W, Wang Y, Long J, Wang J, Haudek SB, Overbeek P, Chang BH, Schumacker PT, Danesh FR. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab. 2012;15:186–200. [PMC free article] [PubMed]
152. Hoffmann J, Haendeler J, Aicher A, Rossig L, Vasa M, Zeiher AM, Dimmeler S. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res. 2001;89:709–715. [PubMed]
153. Uraoka M, Ikeda K, Kurimoto-Nakano R, Nakagawa Y, Koide M, Akakabe Y, Kitamura Y, Ueyama T, Matoba S, Yamada H, Okigaki M, Matsubara H. Loss of bcl-2 during the senescence exacerbates the impaired angiogenic functions in endothelial cells by deteriorating the mitochondrial redox state. Hypertension. 2011;58:254–263. [PubMed]
154. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells Protective effect of nitric oxide. Circ Res. 1997;81:970–976. [PubMed]
155. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteasesA mechanistic clue to the 'response to injury' hypothesis. Circulation. 1997;95:1760–1763. [PubMed]
156. Cheng J, Cui R, Chen CH, Du J. Oxidized low-density lipoprotein stimulates p53-dependent activation of proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology. 2007;148:2085–2094. [PubMed]
157. Rossig L, Hoffmann J, Hugel B, Mallat Z, Haase A, Freyssinet JM, Tedgui A, Aicher A, Zeiher AM, Dimmeler S. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation. 2001;104:2182–2187. [PubMed]
158. Cangiano E, Marchesini J, Campo G, Francolini G, Fortini C, Carra G, Miccoli M, Ceconi C, Tavazzi L, Ferrari R. ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes. Am J Cardiovasc Drugs. 2011;11:189–198. [PubMed]
159. Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plaques. Circulation. 2000;101:2450–2453. [PubMed]
160. Ryter SW, Tyrrell RM. The heme synthesis and degradation pathways: role in oxidant sensitivity Heme oxygenase has both pro- and antioxidant properties. Free Radic Biol Med. 2000;28:289–309. [PubMed]
161. Bourque SL, Benjamin CD, Adams MA, Nakatsu K. Lack of hemodynamic effects after extended heme synthesis inhibition by succinylacetone in rats. J Pharmacol Exp Ther. 2010;333:290–296. [PubMed]
162. Handschin C, Lin J, Rhee J, Peyer AK, Chin S, Wu PH, Meyer UA, Spiegelman BM. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005;122:505–515. [PubMed]
163. Shirihai OS, Gregory T, Yu C, Orkin SH, Weiss MJ. ABC-me: a novel mitochondrial transporter induced by GATA-1 during erythroid differentiation. EMBO J. 2000;19:2492–2502. [PubMed]
164. Liesa M, Luptak I, Qin F, Hyde BB, Sahin E, Siwik DA, Zhu Z, Pimentel DR, Xu XJ, Ruderman NB, Huffman KD, Doctrow SR, Richey L, Colucci WS, Shirihai OS. Mitochondrial transporter ATP binding cassette mitochondrial erythroid is a novel gene required for cardiac recovery after ischemia/reperfusion. Circulation. 2011;124:806–813. [PubMed]
165. Beglova E, Moore C, Roy S, Liesa M, Shirihai OS. Effect of high glucose on expression of a novel mitochondrial transport protein ABC-me in rat retinal endothelial cells. Invest Ophthalmol Vis Sci. 2010;51 pAVRO E-Abstract 5597.
166. Idriss NK, Blann AD, Lip GY. Hemoxygenase-1 in cardiovascular disease. J Am Coll Cardiol. 2008;52:971–978. [PubMed]
167. Alonso JR, Cardellach F, Lopez S, Casademont J, Miro O. Carbon monoxide specifically inhibits cytochrome c oxidase of human mitochondrial respiratory chain. Pharmacol Toxicol. 2003;93:142–146. [PubMed]
168. Rodella LF, Vanella L, Peterson SJ, Drummond G, Rezzani R, Falck JR, Abraham NG. Heme oxygenase-derived carbon monoxide restores vascular function in type 1 diabetes. Drug Metab Lett. 2008;2:290–300. [PubMed]
169. Li FY, Lam KS, Tse HF, Chen C, Wang Y, Vanhoutte PM, Xu A. Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in Mice. Circulation. 2012;126:1267–1277. [PubMed]
170. Liu XM, Peyton KJ, Shebib AR, Wang H, Korthuis RJ, Durante W. Activation of AMPK stimulates heme oxygenase-1 gene expression and human endothelial cell survival. Am J Physiol Heart Circ Physiol. 2011;300:H84–H93. [PubMed]
171. Djordjevic V. delta-Aminolevulinic acid dehydratase activity in erythrocytes of diabetic patients. Arch Int Physiol Biochim. 1985;93:285–290. [PubMed]
172. Smith RA, Hartley RC, Cocheme HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012;33:341–352. [PubMed]
173. Mackenzie RM, Salt IP, Miller WH, Logan A, Ibrahim HA, Degasperi A, Dymott JA, Hamilton CA, Murphy MP, Delles C, Dominiczak AF. Mitochondrial reactive oxygen species enhance AMP-activated protein kinase activation in the endothelium of patients with coronary artery disease and diabetes. Clin Sci (Lond) 2013;124:403–411. [PubMed]
174. Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem. 2004;279:37575–37587. [PubMed]
175. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, Timmons M, Motta A, Phillips SA, Hari P. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011;301:H2305–H2312. [PubMed]
176. Graham D, Huynh NN, Hamilton CA, Beattie E, Smith RA, Cocheme HM, Murphy MP, Dominiczak AF. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54:322–328. [PubMed]
177. Snow BJ, Rolfe FL, Lockhart MM, Fra mpton CM, O'Sullivan JD, Fung V, Smith RA, Murphy MP, Taylor KM. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord. 2010;25:1670–1674. [PubMed]
178. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int. 2010;30:1019–1026. [PubMed]
179. Hagen TM, Ingersoll RT, Wehr CM, Lykkesfeldt J, Vinarsky V, Bartholomew JC, Song MH, Ames BN. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA. 1998;95:9562–9566. [PubMed]
180. Hagen TM, Moreau R, Suh JH, Visioli F. Mitochondrial decay in the aging rat heart: evidence for improvement by dietary supplementation with acetyl-L-carnitine and/or lipoic acid. Ann N Y Acad Sci. 2002;959:491–507. [PubMed]
181. Zhang WJ, Frei B. Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J. 2001;15:2423–2432. [PubMed]
182. Visioli F, Smith A, Zhang W, Keaney JF, Jr., Hagen T, Frei B. Lipoic acid and vitamin C potentiate nitric oxide synthesis in human aortic endothelial cells independently of cellular glutathione status. Redox Rep. 2002;7:223–227. [PubMed]
183. Marsh SA, Laursen PB, Pat BK, Gobe GC, Coombes JS. Bcl-2 in endothelial cells is increased by vitamin E and alpha-lipoic acid supplementation but not exercise training. J Mol Cell Cardiol. 2005;38:445–451. [PubMed]
184. Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Circulation. 2008;117:421–428. [PubMed]
185. Smith AR, Hagen TM. Vascular endothelial dysfunction in aging: loss of Akt-dependent endothelial nitric oxide synthase phosphorylation and partial restoration by (R)-alpha-lipoic acid. Biochem Soc Trans. 2003;31:1447–1449. [PubMed]
186. Heinisch BB, Francesconi M, Mittermayer F, Schaller G, Gouya G, Wolzt M, Pleiner J. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest. 2010;40:148–154. [PubMed]
187. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV. Irbesartan lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome. Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study. Circulation. 2005;111:343–348. [PubMed]
188. Shankar SS, Mirzamohammadi B, Walsh JP, Steinberg HO. L-carnitine may attenuate free fatty acid-induced endothelial dysfunction. Ann N Y Acad Sci. 2004;1033:189–197. [PubMed]
189. Rippe C, Lesniewski L, Connell M, LaRocca T, Donato A, Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell. 2010;9:304–312. [PMC free article] [PubMed]
190. Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO. Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 2005;310:314–317. [PubMed]
191. Fujisawa K, Nishikawa T, Kukidome D, Imoto K, Yamashiro T, Motoshima H, Matsumura T, Araki E. TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun. 2009;379:43–48. [PubMed]
192. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001;37:1344–1350. [PubMed]
193. Abdellatif M. Sirtuins and pyridine nucleotides. Circ Res. 2012;111:642–656. [PMC free article] [PubMed]
194. Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT, Tschop MH. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev. 2012;92:1479–1514. [PMC free article] [PubMed]
195. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113–118. [PubMed]
196. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007;26:1913–1923. [PubMed]
197. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000;20:1868–1876. [PMC free article] [PubMed]
198. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A. 2002;99:13653–13658. [PubMed]
199. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes MW, Olivier AK, Spitz DR, Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell. 2010;40:893–904. [PMC free article] [PubMed]
200. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 2007;104:14855–14860. [PubMed]
201. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, Haendeler J, Mione M, Dejana E, Alt FW, Zeiher AM, Dimmeler S. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21:2644–2658. [PubMed]
202. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA, Seals DR. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. J Physiol. 2011;589:4545–4554. [PubMed]
203. Hasegawa Y, Saito T, Ogihara T, Ishigaki Y, Yamada T, Imai J, Uno K, Gao J, Kaneko K, Shimosawa T, Asano T, Fujita T, Oka Y, Katagiri H. Blockade of the nuclear factor-kappaB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation. 2012;125:1122–1133. [PubMed]
204. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506. [PubMed]
205. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes. 2006;55:2180–2191. [PubMed]
206. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol. 2009;297:H13–H20. [PubMed]
207. Ungvari Z, Labinskyy N, Mukhopadhyay P, Pinto JT, Bagi Z, Ballabh P, Zhang C, Pacher P, Csiszar A. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol. 2009;297:H1876–H1881. [PubMed]
208. Brito PM, Simoes NF, Almeida LM, Dinis TC. Resveratrol disrupts peroxynitrite-triggered mitochondrial apoptotic pathway: a role for Bcl-2. Apoptosis. 2008;13:1043–1053. [PubMed]
209. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2010;21:851–856. [PubMed]
210. Cassidy-Stone A, Chipuk JE, Ingerman E, Song C, Yoo C, Kuwana T, Kurth MJ, Shaw JT, Hinshaw JE, Green DR, Nunnari J. Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell. 2008;14:193–204. [PMC free article] [PubMed]
211. Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121:2012–2022. [PubMed]
212. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11:860–872. [PubMed]
213. Chan SY, Zhang YY, Hemann C, Mahoney CE, Zweier JL, Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009;10:273–284. [PMC free article] [PubMed]